Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16074890 | 0.94 | THRB (0.50) | THRBPTPN1FFAR4ACACBACACA | |
| SCHEMBL16074721 | 0.94 | THRB (0.50) | THRBPTPN1FFAR4ACACBACACA | |
| SCHEMBL16074963 | 0.94 | THRB (0.50) | THRBPTPN1FFAR4ACACBACACA | |
| SCHEMBL16074836 | 0.94 | THRB (0.50) | THRBPTPN1FFAR4ACACBACACA | |
| SCHEMBL16074802 | 0.94 | THRB (0.50) | THRBPTPN1FFAR4ACACBACACA | |
| SCHEMBL16074834 | 0.94 | THRB (0.50) | THRBPTPN1FFAR4ACACBACACA | |
| SCHEMBL16074800 | 0.94 | THRB (0.50) | THRBPTPN1FFAR4ACACBACACA | |
| SCHEMBL21566550 | 0.94 | THRB (0.50) | THRBPTPN1FFAR4ACACBACACA | |
| SCHEMBL16074844 | 0.94 | THRB (0.50) | THRBPTPN1FFAR4ACACBACACA | |
| SCHEMBL6744315 | 0.94 | THRB (0.50) | THRBPTPN1FFAR4ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062720-A1 | Multifunctional Fatty Acid Derivatives And Biosynthesis Thereof | AGAIN BIO APS (DK) | 2026-03-05 | — | — | US | claimed |
| US-20240309405-A1 | MULTIFUNCTIONAL FATTY ACID DERIVATIVES AND BIOSYNTHESIS THEREOF | OXFORD FINANCE LLC | 2024-09-19 | — | — | US | claimed |
| US-20260062720-A1 | Multifunctional Fatty Acid Derivatives And Biosynthesis Thereof | AGAIN BIO APS (DK) | 2026-03-05 | — | — | US | disclosed |
| US-20240309405-A1 | MULTIFUNCTIONAL FATTY ACID DERIVATIVES AND BIOSYNTHESIS THEREOF | OXFORD FINANCE LLC | 2024-09-19 | — | — | US | disclosed |
| US-20210189439-A1 | Multifunctional Fatty Acid Derivatives And Biosynthesis Thereof | GENOMATICA, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| WO-2019217226-A1 | MULTIFUNCTIONAL FATTY ACID DERIVATIVES AND BIOSYNTHESIS THEREOF | REG Life Sciences, LLC (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062720-A1 | Multifunctional Fatty Acid Derivatives And Biosynthesis Thereof | FASN, FFAR1, FFAR3 | THRB 795/4885PTPN1 1779/4885FFAR4 18/4885 |
| US-20240309405-A1 | MULTIFUNCTIONAL FATTY ACID DERIVATIVES AND BIOSYNTHESIS THEREOF | DGAT2, DGAT1, FASN | THRB 2408/4885PTPN1 1903/4885FFAR4 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.